Phillyrin

SKU: orb1304927

Description

Phillyrin

Research Area

Epigenetics & Chromatin, Infectious Disease & Virology, Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 487-41-2
• MW: 534.55
• Purity: 98.28% (May vary between batches)
• Formula: C₂₇H₃₄O₁₁
• SMILES: COc1ccc(cc1OC)[C@@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1OC
• Target: AMPK,Influenza Virus,Cytochromes P450,Antibacterial
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (6.17 mM);DMSO:91 mg/mL (170.24 mM)

Bioactivity

• In Vivo:
  Phillyrin has anti-obesity effect in nutritive obesity mice. Phillyrin could lower wet weight of fat (P < 0.01), fat index (P < 0.05 or P < 0.01), the diameter of fat cell and Lee's index (P < 0.05), decrease the jejunum microvillus area, lower the level of serum triglyceride and cholesterol.
• In Vitro:
  Phillyrin suppressed high glucose-induced lipid accumulation in HepG2 cells. Phillyrin strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation. Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor revealed that AMPK is essential for suppressing SREBP-1c expression in Phillyrin-treated cells. Liver kinase B1 (LKB1) phosphorylation is required for the Phillyrin-enhanced activation of AMPK in HepG2 hepatocytes.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Cytochrome P450, CYPs, AMPK, Forsythin, Inhibitor, inhibit, InfluenzaVirus, Influenza Virus, Phillyrin

Compound Identifiers

PubChem CID

24721571